POMBILITI Amicus Therapeutics Pty Ltd
Product name
POMBILITI
Sponsor
Accepted date
Jan-2024
Active ingredients
cipaglucosidase alfa
Proposed indication
For the treatment of adults with late-onset Pompe disease (acid α glucosidase [GAA] deficiency)
Application type
A (new medicine)
Publication date
Jan-2024